VistaGen Therapeutics's total inventories for the quarter that ended in Dec. 2021 was $0.00 Mil. VistaGen Therapeutics's average total inventories from the quarter that ended in Sep. 2021 to the quarter that ended in Dec. 2021 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. VistaGen Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2021 was $0.35.
Inventory can be measured by days sales of inventory (DSI).
VistaGen Therapeutics's days sales of inventory (DSI) for the
three
months ended in Dec. 2021 was 0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
VistaGen Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2021 was 0.00.
VistaGen Therapeutics Total Inventories Historical Data
The historical data trend for VistaGen Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
VistaGen Therapeutics Annual Data
Trend
Mar12
Mar13
Mar14
Mar15
Mar16
Mar17
Mar18
Mar19
Mar20
Mar21
Total Inventories
-
-
-
-
-
VistaGen Therapeutics Quarterly Data
Mar17
Jun17
Sep17
Dec17
Mar18
Jun18
Sep18
Dec18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Total Inventories
-
-
-
-
-
VistaGen Therapeutics Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
VistaGen Therapeutics (NAS:VTGN) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
VistaGen Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2021 is
5. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
VistaGen Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
VistaGen Therapeutics Total Inventories Related Terms
Thank you for viewing the detailed overview of VistaGen Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.
VistaGen Therapeutics Inc is a biotechnology firm. The company is in its clinical stage and engaged in developing and commercializing product candidates for patients with diseases and disorders involving the central nervous system. Its lead product candidate, AV-101, is an orally available prodrug candidate in Phase II development, initially for the adjunctive treatment of a major depressive disorder in patients with an inadequate response to standard antidepressants. The PH94B is a novel neuroactive nasal spray with therapeutic potential in a wide range of indications involving anxiety or phobia; PH10 is an odorless, fast-acting synthetic neurosteroid for neuropsychiatric indications involving depression.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0.06(5.41%) Volume: 1,357,425 8:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:VTGN has been successfully added to your 
